SCYNEXIS Eulerpool News

SCYNEXIS Stock News

SCYNEXIS is being monitored by journalists and investors worldwide. We gather the latest SCYNEXIS news here.

• December 22 ·

  Yahoo
  SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
• December 22 ·

  Benzinga
  SCYNEXIS Receives Nasdaq Extension To Regain Bid Price Compliance By June 15, 2026
• November 25 ·

  Benzinga
  12 Health Care Stocks Moving In Tuesday's Pre-Market Session
• November 19 ·

  Yahoo
  SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
• November 19 ·

  Benzinga
  SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
• November 10 ·

  Yahoo
  Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
• October 15 ·

  Benzinga
  SCYNEXIS To Receive $22M From GlaxoSmithKline To Resolve Dispute Over Restarting The Phase 3 Mario Study For Invasive Candidiasis.
• September 30 ·

  Benzinga
  SCYNEXIS Reports Results From Phase 1 Study Of SCY-247, Second-Gen Triterpenoid Antifungal Under Development For Treatment And Prevention Of Invasive Fungal Infections
• May 29 ·

  Yahoo
  SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
• April 8 ·

  Yahoo
  SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

SCYNEXIS Stock Press Releases

SCYNEXIS regularly publishes news on the company's website that are relevant for investors.